Brainsway Ltd.

Enlight Renewable Energy Ltd.: The Company may double its revenues within two years; price target is NIS 2.30.

Read More »

Enlight Renewable Energy Ltd: Significant regualtory progress brings Enlight closer to final-stage approvals for the Bereshit wind farm; stock target price unchanged.

Read More »

Enlight Renewable Energy Ltd: Revenues from sales of electricity in 2017 met expectations; full commercial operation in Ireland; a growing project pipeline; stock target price remains at 2.30.

Read More »

Energix Renewable Energies Ltd.: Combining green energy growth opportunities with Fix Assets returns

Read More »

Energix: Entering the US market is a significant long-term growth opportunity; major project and regulatory milestones in Poland and Israel increase installed capacity; new in-house O&M and project management capabilities improve financial and operational efficiency; target price raised to NIS 4.05.

Read More »

Energix: Polish Power Exchange reforms have a positive effect; stake in Ilawa Wind Energy project in Poland increased from 75% to 100%; all projects in development are progressing according to schedule; target price raised to NIS 4.61

Read More »

Energix Renewable Energies Ltd.: Completion of stage II connection to the company’s flagship Polish project and successful capital raising are positive indicators. We have raised the price target to NIS 3.82.

Read More »

Energix Renewable Energies Ltd.: The revenues in H1 2017 attest the implementation of plans and expected growth in cash flows from projects. Target Price Unchanged.

Read More »

DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.

Read More »

DNA Biomedical Solutions Ltd.: The company and its holdings can become a major force in the osteoporosis care market, pending success in next year’s clinical trials.

Read More »